As Samsung Biologics’ contract manufacturing business continues to fire on all cylinders, the CDMO has earned a unique ...
The designation applies to investigational therapies that target rare diseases affecting less than 200,000 people in the US.
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
January 21, 2026-- Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology th ...
Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
Zura Bio Limited said it has appointed Sandeep Kulkarni as chief executive, effective Wednesday. The clinical-stage biotechnology company said Kulkarni will continue serving as a director. Kulkarni ...
Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results